Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274521 · ClinicalTrials.gov registry record · Phase 3
Tiotropium (Spiriva) Rehabilitation Study
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
NCT00274521 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 108 participants.
The verdict
NCT00274521, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
Study Summary
The study was designed to determine whether tiotropium inhalation capsules, compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in pulmonary rehabilitation. In addition, assessments of the effect of tiotropium on dyspnea and quality of life following pulmonary rehabilitation were taken.
Interventions
- DRUG Tiotropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2001-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274521
The ClinicalTrials.gov registry entry for NCT00274521 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tiotropium is the first listed.
NCT00274521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274521 about?
NCT00274521 is a clinical study titled "Tiotropium (Spiriva) Rehabilitation Study". The study was designed to determine whether tiotropium inhalation capsules, compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in pulmonary rehabilitation. In addition, assessments of the effect of ti...
What is the current status of trial NCT00274521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2001-05.
What interventions are being tested in trial NCT00274521?
The interventions under investigation include: Tiotropium (DRUG).
Who is sponsoring clinical trial NCT00274521?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.